Biorce, a pioneering biotech startup specializing in artificial intelligence for clinical trial design, is making significant strides with the opening of its new headquarters in Barcelona. This move follows a successful funding round that secured €52.5 million, positioning the company for substantial growth.
Major Expansion Plans
After an impressive year and a half of rapid development, Biorce is gearing up to close 2026 with an anticipated revenue of €12 million and a workforce that will expand from the initial 12 employees to 250. The company’s decision to establish its own office reflects its growing needs, as they transition to a 2,000 square meter space in the El Dau building located on Barcelona’s Avenida Diagonal.
This new location marks a significant escalation in Biorce’s operational capacity, especially after beginning its journey at the Norrsken Foundation in a modest 200 square meters. The move to El Dau, which once housed AstraZeneca, situates Biorce in one of the city’s key business districts.
Funding Success and Future Growth
Biorce’s expansion comes on the heels of securing €44 million in a Series A funding round, which is one of the largest investments a healthtech startup has received in Spain to date. Led by DST Global, the round also saw participation from existing investors like Norrsken VC, YZR Capital, and Mustard Seed Maze, alongside newcomers such as Endeavor Catalyst.
Notable figures from various sectors, including Nik Storonsky, CEO of Revolut, and Arthur Mensch, CEO of Mistral AI, have also invested in Biorce, highlighting the company’s promising potential.
The Vision Behind Biorce
Founded in mid-2024 by Pedro Coelho, Diogo Pisoeiro, Clara Bernardes, and José Faria, Biorce aims to streamline the design and execution of clinical trials. Their approach focuses on reducing inefficiencies within the system, from patient selection to hospital partnerships.
At the heart of Biorce’s innovation is Aika, an AI-powered assistant built on a robust database comprising over a million clinical trials, protocols, and scientific and regulatory data. Aika facilitates the creation of faster, more reliable, and accessible studies, ultimately accelerating patient access to new treatments.
A Strategic Location for Growth
Biorce’s new headquarters, managed by Colonial SFL and advised by BNP Paribas Real Estate, boasts nine floors with spaces ranging from 500 to 2,000 square meters, totaling 22,000 square meters. Located in the Central Business District (CBD), this prime location is strategically chosen to support Biorce’s international expansion, attract top talent, and foster a multidisciplinary team capable of leading technological transformations in clinical trials globally.
Hiring for the Future
From this new office, Biorce plans to onboard 250 new employees by the end of the year, particularly focusing on technical and commercial roles. These positions will be distributed between the Barcelona headquarters and a new research and development center established in Austin, Texas.
Conclusion
Biorce’s relocation to El Dau marks a significant milestone in its journey, reflecting its ambitious growth trajectory and commitment to innovation in the biotech sector. As the company prepares to expand its workforce and capabilities, it stands poised to revolutionize the clinical trial landscape, enhancing the efficiency and accessibility of medical treatments for patients worldwide.
- Key Takeaways:
- Biorce is expanding its headquarters to 2,000 square meters in Barcelona to accommodate growth.
- Recent funding of €52.5 million positions Biorce as a leader in healthtech innovation.
- The company aims to hire 250 employees by the end of the year as part of its expansion efforts.
Read more → www.elperiodico.com